<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1323">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412668</url>
  </required_header>
  <id_info>
    <org_study_id>ATYR1923-C-003</org_study_id>
    <nct_id>NCT04412668</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19</brief_title>
  <official_title>A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aTyr Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>aTyr Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study to evaluate the safety and preliminary efficacy of ATYR1923, compared to
      placebo, in hospitalized patients with SARS-CoV-2 (COVID-19) severe pneumonia not requiring
      mechanical ventilation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1:1 to a single IV dose of ATYR1923 1 mg/kg, ATYR1923 3 mg/kg, or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Investigator, Sponsor, and patient will be blinded to treatment assignment; study center pharmacy personnel will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline through Day 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of oxygen saturation (SpO2) (&gt;93% on room air sustained for at least 24 hours)</measure>
    <time_frame>Baseline through Day 14 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen (O2) requirement</measure>
    <time_frame>Baseline through Day 14 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with fever (temperature &gt;100.4ºF [38.0ºC])</measure>
    <time_frame>Baseline through Day 14 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of temperature (≤100.4ºF [38.0ºC])</measure>
    <time_frame>Baseline through Day 14 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60</measure>
    <time_frame>Baseline through Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score</measure>
    <time_frame>Baseline through Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>SARS-CoV-2 (COVID-19) Severe Pneumonia</condition>
  <arm_group>
    <arm_group_label>ATYR1923 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ATYR1923 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATYR1923 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of ATYR1923 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATYR1923 1 mg/kg</intervention_name>
    <description>1 mg/kg of ATYR1923 administered intravenously</description>
    <arm_group_label>ATYR1923 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATYR1923 3 mg/kg</intervention_name>
    <description>3 mg/kg of ATYR1923 administered intravenously</description>
    <arm_group_label>ATYR1923 3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of SARS-CoV2 infection by PCR.

          -  Severe pneumonia related to SARS-CoV2 infection, defined as fever or suspected
             respiratory infection with radiographic abnormalities suggestive of viral pneumonia,
             plus at least one of the following:

               -  Respiratory rate &gt;30 breaths/min; or

               -  Severe respiratory distress, as determined by the Investigator; or;

               -  SpO2 ≤93% on room air.

        Exclusion Criteria:

          -  Patient is intubated/mechanically ventilated.

          -  In the opinion of the Investigator, patient's progression to death is imminent.

          -  Treatment with immunosuppressant/immunotherapy drugs, including but not limited to
             IL-6 inhibitors, TNF-α inhibitors, anti-IL-1 agents and janus kinase inhibitors within
             5 half-lives or 30 days prior to Day 1.

          -  Use of chronic (&gt;30 days) oral corticosteroids for a non COVID 19-related condition in
             a dose higher than prednisone 10 mg or equivalent per day.

          -  Weight &gt;165 kg or &lt;40 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennyne Walker</last_name>
    <role>Study Director</role>
    <affiliation>aTyr Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>aTyr Pharma Clinical Research</last_name>
    <phone>877-215-5731</phone>
    <email>clinicaltrials@atyrpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Duncan, MD</last_name>
      <phone>205-934-5018</phone>
      <email>srduncan@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Duncan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@atyrpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Mirsaeidi, MD, MPH</last_name>
      <phone>305-243-9227</phone>
      <email>msm249@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mehdi Mirsaeidi, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Comellas, MD</last_name>
      <phone>319-353-8862</phone>
      <email>alejandro-comellas@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Alejandro Comellas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@atyrpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@atyrpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shambhu Aryal, MD</last_name>
      <email>shambhu.aryal@inova.org</email>
    </contact>
    <investigator>
      <last_name>Shambhu Aryal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manati Medical Center</name>
      <address>
        <city>Manatí</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel A Amill</last_name>
      <phone>787 621 3266</phone>
      <email>samuelaamill@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Samuel A Amill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>CoV-2</keyword>
  <keyword>ATYR1923</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>ARDS</keyword>
  <keyword>SARS-CoV-2 Infection</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Severe Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

